1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Opioid Receptor Antagonists -Pipeline Insights, 2016

Opioid Receptor Antagonists -Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “Opioid Receptor Antagonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Opioid Receptor Antagonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Opioid Receptor Antagonists. DelveInsight’s Report also assesses the Opioid Receptor Antagonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Opioid Receptor Antagonists
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Opioid Receptor Antagonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Opioid Receptor Antagonists and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Opioid Receptor Antagonists -Pipeline Insights, 2016

- Opioid Receptor Antagonists Overview
- Opioid Receptor Antagonists Disease Associated
- Opioid Receptor Antagonists Pipeline Therapeutics
- Opioid Receptor Antagonists Therapeutics under Development by Companies
- Opioid Receptor Antagonists Filed and Phase III Products
- Comparative Analysis
- Opioid Receptor Antagonists Phase II Products
- Comparative Analysis
- Opioid Receptor Antagonists Phase I and IND Filed Products
- Comparative Analysis
- Opioid Receptor Antagonists Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Opioid Receptor Antagonists - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Opioid Receptor Antagonists - Discontinued Products
- Opioid Receptor Antagonists - Dormant Products
- Companies Involved in Therapeutics Development for Opioid Receptor Antagonists
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Opioid Receptor Antagonists by Therapy Area, 2016
- Number of Products under Development for Opioid Receptor Antagonists, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Opioid Receptor Antagonists Assessment by Monotherapy Products
- Opioid Receptor Antagonists Assessment by Combination Products
- Opioid Receptor Antagonists Assessment by Route of Administration
- Opioid Receptor Antagonists Assessment by Stage and Route of Administration
- Opioid Receptor Antagonists Assessment by Molecule Type
- Opioid Receptor Antagonists Assessment by Stage and Molecule Type
- Opioid Receptor Antagonists Therapeutics - Discontinued Products
- Opioid Receptor Antagonists Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Opioid Receptor Antagonists by Therapy Area, 2016
- Number of Products under Development for Opioid Receptor Antagonists, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Opioid Receptor Antagonists Assessment by Monotherapy Products
- Opioid Receptor Antagonists Assessment by Combination Products
- Opioid Receptor Antagonists Assessment by Route of Administration
- Opioid Receptor Antagonists Assessment by Stage and Route of Administration
- Opioid Receptor Antagonists Assessment by Molecule Type
- Opioid Receptor Antagonists Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The North America opioid market is expected to reach USD 18.5 billion by 2024, according to a new report by Grand View Research, Inc. Favorable regulations and healthcare reforms are providing an environment, ...

Global Market Study on Opioids: Widespread Usage in Treatment of Cancer to Drive the Growth of Opioids Market During the Forecast Period

Global Market Study on Opioids: Widespread Usage in Treatment of Cancer to Drive the Growth of Opioids Market During the Forecast Period

  • $ 4900
  • Industry report
  • August 2016
  • by Persistence Market Research

Opioids are naturally occurring opiates and synthetic and semi-synthetic drugs that act on opioid receptors in the brain and can cause dependence due to their euphoric effects. Opioids are majorly categorized ...

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

  • $ 3080
  • Industry report
  • September 2016
  • by MP Advisors

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing ...


Download Unlimited Documents from Trusted Public Sources

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Opioid and Anesthetics Market in Australia

  • December 2016
    5 pages
  • Opioid  

    Anesthetics  

    Analgesic  

  • Australia  

View report >

Related Market Segments :

Opioid

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.